Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Implications of Genomic and Genetic Testing for the Management of Prostate Cancer Patients

New E-Learning module by Dr Llácer Pérez and Dr Castro is now available. Watch the presentation and take the CME test today!

E-learning video block

This content is for ESMO members only.



Download slides

Learning objectives

  1. Understand the genomic heterogeneity of advanced prostate cancer and the implications for patient stratification and therapeutic decision making​
  2. Learn the prevalence and clinical implications of somatic and germline DDR alterations in advanced prostate cancer​
  3. Know the principal studies conducted with PARP inhibitors in prostate cancer, highlighting the paradigm shift in the management of the disease ​
  4. Highlight the importance of optimising tumour profiling and the relevance of germline testing​


Prostate cancer has entered in a new era of precision medicine with therapies being developed to target the pathways more frequently altered in advanced prostate cancer​. In this E-Learning module, the authors present the genomic landscape and actionable alterations in advanced prostate cancer and highlight the findings from the clinical studies that necessitate the changes in clinical practice.

The outline of the module is divided into chapters on genomic testing for precision medicine​, prevalence of somatic and germline DNA damage repair (DDR) alterations, impact of DDR alterations in advanced prostate cancer​, PARP inhibitors to treat homologous recombination repair (HRR) deficient metastatic castration-resistant prostate cancer (mCRPC), platinum based chemotherapy to treat HRR deficient mCRPC​, AKT inhibitors to treat PTEN deficient mCRPC​, other targeted therapies under development for advanced prostate cancer, considerations for genomic testing in prostate cancer​, and recommendations for germline testing.  ​

Based on the results from recent studies, the authors underline that tumour profiling will be required to select the most appropriate therapy for advanced prostate cancer. Optimisation of tissue collection is critical to improve tumour profiling​. Metastatic biopsy is the preferred method for testing, but some early events could be detected in the primary tumours​. Liquid biopsy may help overcome some limitations of tissue testing​.

Furthermore, the authors emphasise that germline testing should be offered to all men with metastatic prostate cancer and to those with tumour alterations in​ cancer-predisposition genes​.

This E-Learning module provides an excellent overview of results from the recent clinical studies, illustrates the status of guidelines where those findings resulted in change of recommendations for clinical practice and emphasises the need for tumour profiling to select the therapy, as well as for offering germline testing to all men with metastatic prostate cancer. 

Declaration of interest

Casilda Llácer Pérez has reported:
Speaker honoraria from Roche.

Elena Castro has reported:
Research funding from AstraZeneca, Bayer and Janssen.
Speaker honoraria from Astellas, AstraZeneca, Bayer, Janssen.
Advisory boards: Bayer, Janssen.
Travel and accommodation expenses from Astellas, AstraZeneca, Bayer, Janssen and Roche.
Consultancy: AstraZeneca and Pfizer.

Last update: 04 May 2021

This E-Learning module was published in 2021. The CME test expired in 2023.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.